免疫联合靶向治疗预防肝细胞癌行ALPPS术后复发的临床疗效  

Clinical efficacy of immunotherapy plus target therapy for preventing postoperative recurr-ence of hepatocellular carcinoma after associating liver partition and portal vein ligation for staged hepatectomy

作　　者：尚敏杰[1] 张军港[1] 顾宗庭 魏芳强 陶然 吴国清[2] 文阳[3] 沈坚 唐雨琪 Shang Minjie;Zhang Jungang;Gu Zongting;Wei Fangqiang;Tao Ran;Wu Guoqing;Wen Yang;Shen Jian;Tang Yuqi(Department of Hepatobiliary and Pancreatic Surgery,Minimal Invasive Surgery,Zhejiang Provincial People's Hospital,Hangzhou 310014,China;Department of Oncology,Zhejiang Provincial People's Hospital,Hangzhou 310014,China;Department of Radiology,Zhejiang Provincial People's Hospital,Hangzhou 310014,China;Hangzhou Medical College,Hangzhou 310059,China)

机构地区：[1]浙江省人民医院肝胆胰腺外科微创外科,杭州310014 [2]浙江省人民医院肿瘤内科,杭州310014 [3]浙江省人民医院放射科,杭州310014 [4]杭州医学院,杭州310059

出　　处：《中华消化外科杂志》2023年第2期281-285,共5页Chinese Journal of Digestive Surgery

基　　金：浙江省省部共建重大项目(WKJ-ZJ-1901)。

摘　　要：原发性肝癌晚期患者手术切除存在因剩余肝脏体积不足,行二步肝癌切除术后早期复发和伴门静脉癌栓发生率高的风险。目前,针对这类患者的治疗手段十分有限,患者的治疗需求无法得到满足。笔者报道1例肝细胞癌剩余肝脏体积不足,行二步肝癌切除术后预防性使用免疫联合靶向治疗的临床经验,旨在为相关治疗提供参考。Surgical resection in patients with advanced primary carcinoma of liver has high risks of early recurrence and incidence of portal vein tumor thrombus,caused by insufficient resi-dual liver volume after two-steps hepatotomy.At present,the treatment for patients with advanced primary carcinoma of liver is limited,thus can't satisfy the requirement of patient for treatment.The authors introduce the clinical experience of a patient with hepatocellular carcinoma and insufficient residual liver volume who underwent preventive immunotherapy plus target therapy after associa-ting liver partition and portal vein ligation for staged hepatectomy,in order to provide reference for relevant treatment.

关 键 词：肝肿瘤 剩余肝脏体积 二步肝切除术 肿瘤复发 靶向治疗 免疫治疗 预后 

分 类 号：R735.7[医药卫生—肿瘤]